Cannabidiol (CBD)

Review

Hannah Meissner¹, Marco Cascella²

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.

2021 Jul 17.

Affiliations

PMID: 32310508
Bookshelf ID: NBK556048

Free Books & Documents

Excerpt

CBD is a medication used to manage and treat the seizure disorders Lennox-Gastaut syndrome and Dravet syndrome. This activity describes the indications, action, and contraindications for CBD as a valuable agent in the treatment and management of Lennox-Gastaut syndrome and Dravet syndrome, and also highlights the mechanism of action, adverse event profile, and other key factors such as current research trials ongoing for CBD use.

Sections

Similar articles

Don’t Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.

Perry MS.Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671.PMID: 30955420 Free PMC article.
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.

Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA, Weinstock A; CBD EAP study group.Epilepsy Res. 2019 Aug;154:13-20. doi: 10.1016/j.eplepsyres.2019.03.015. Epub 2019 Mar 25.PMID: 31022635 Clinical Trial.
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Chen JW, Borgelt LM, Blackmer AB.Ann Pharmacother. 2019 Jun;53(6):603-611. doi: 10.1177/1060028018822124. Epub 2019 Jan 8.PMID: 30616356 Review.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.

Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, Brigo F.CNS Drugs. 2021 Mar;35(3):265-281. doi: 10.1007/s40263-021-00807-y. Epub 2021 Mar 22.PMID: 33754312 Free PMC article.
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.

Golub V, Reddy DS.Adv Exp Med Biol. 2021;1264:93-110. doi: 10.1007/978-3-030-57369-0_7.PMID: 33332006 Review.

See all similar articles

References

1. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2(1):139-154. – PMC – PubMed
1. Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 2019;9:2045125319881916. – PMC – PubMed
1. Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, Wang Y, Liang C. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. Eur J Med Chem. 2020 Apr 15;192:112163. – PubMed
1. Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules. 2019 Apr 12;24(8) – PMC – PubMed
1. Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety. CNS Drugs. 2020 Mar;34(3):229-241. – PubMed

Publication types

LinkOut – more resources

Full Text Sources
- NCBI Bookshelf

Excerpt

Sections

Similar articles

References

Publication types

LinkOut – more resources

Full Text Sources

Freedom Wares

Previous PostChanges in Hepatic Phospholipid Metabolism in Rats under UV Irradiation and Topically Treated with Cannabidiol

Next PostMedical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review